CRESCENT BIOPHARMA, INC.
CBIONasdaqHealthcare · Pharmaceutical Preparations · E9 · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $10.8M | $0 | $10,000 | $75,000 | $1.2M | $10.2M |
| Operating income | −$152.6M | −$17.2M | −$39.3M | −$47.4M | −$63.4M | −$51.5M |
| Net income | −$153.9M | −$17.9M | −$36.9M | −$46.7M | −$63.4M | −$51.0M |
| Total assets | $240.3M | $35.6M | $45.3M | $51.8M | $94.3M | $142.8M |
| Total liabilities | $37.3M | $47.1M | $6.9M | $8.9M | $12.7M | $14.6M |
| Equity | $203.0M | $0 | $38.4M | $42.9M | $81.6M | $128.2M |
| EPS (diluted) | — | $-0.59 | $-0.58 | $-0.89 | $-1.23 | $-1.12 |
| Shares out. | 64.5M | 64.5M | 64.2M | 52.3M | 51.5M | 43.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −1407.5%
- Net margin
- −1419.6%
- Return on equity
- −75.8%
- Return on assets
- −64.1%
- Return on capital (ROCE)
- −74.7%
- Liabilities / assets
- 15.5%
- Debt / equity
- 0.18×
- Book value / share
- $3.15
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 4.59safe
- Accruals / assets
- −34.3%clean
- Piotroski F-Score
- 4/8mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 3 warning● 3 good- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Tang Capital Management LlcPassive (13G)May 15, 2026
- Balyasny Asset Management L.P.Passive (13G)May 15, 2026
- Venrock Healthcare Capital Partners Iii, L.P.Passive (13G)Feb 17, 2026
- Vestal Point Capital, LpPassive (13G)Feb 17, 2026
- Fmr LlcPassive (13G)Feb 5, 2026
- Forgrowth Iii Pa B.V.Passive (13G)Dec 11, 2025
- Fairmount Funds Management LlcActivist (13D)Dec 8, 2025
- 1globe Capital LlcPassive (13G)Oct 14, 2025
- Logos Global Management LpPassive (13G)Aug 14, 2025
- Biotechnology Value Fund L PPassive (13G)Aug 14, 2025
- Adage Capital Management, L.P.Activist (13D)Jun 20, 2025
- Ra Capital Management, L.P.Passive (13G)Feb 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 2.9M | 8.4 | +21.1% |
| Apr 30, 2026 | 2.4M | 8.9 | +7.5% |
| Apr 15, 2026 | 2.2M | 8.7 | -0.5% |
| Mar 31, 2026 | 2.2M | 9.1 | +54.6% |
| Mar 13, 2026 | 1.4M | 9.7 | +0.1% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsApr 29, 2026
- Results of operationsFeb 26, 2026
- Entered a material agreement · Unregistered equity sale · Regulation FD disclosure · Other material eventDec 4, 2025
- Results of operationsNov 6, 2025
- Results of operations · Director / officer changeJul 31, 2025
- Entered a material agreement · Completed an acquisition or disposition · Results of operations · Modified shareholder rights · Changed auditor · Change in control · Director / officer change · Amended charter or bylaws · Item 5.05 · Item 5.06 · Regulation FD disclosureJun 18, 2025
- Shareholder vote · Regulation FD disclosure · Other material eventJun 6, 2025
- Other material eventMay 30, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.